Restrictive versus liberal red cell transfusion strategies in patients with acute myocardial infarction: a systematic review and meta-analysis

Yuanhui Liu  
Guangdong Academy of Medical Sciences: Guangdong Provincial People's Hospital

Yeshen Zhang  
Guangdong Academy of Medical Sciences: Guangdong Provincial People's Hospital

Yuming Huang  
Guangdong Academy of Medical Sciences: Guangdong Provincial People's Hospital

Nianjin Xie  
Guangdong Academy of Medical Sciences: Guangdong Provincial People's Hospital

Lihuan Zeng  
Guangdong Academy of Medical Sciences: Guangdong Provincial People's Hospital

Xingji Lian  
Sun Yat-sen University First Affiliated Hospital

Jijin Lin  
Guangdong Academy of Medical Sciences: Guangdong Provincial People's Hospital

Yining Dai  
Guangdong Academy of Medical Sciences: Guangdong Provincial People's Hospital

Jiyan Chen  
Guangdong Academy of Medical Sciences: Guangdong Provincial People's Hospital

Pengcheng He  
Guangdong Academy of Medical Sciences: Guangdong Provincial People's Hospital

Ning Tan (gdtanning@126.com)  
https://orcid.org/0000-0002-6185-7126

Research

Keywords: Acute myocardial infarction, Anemia, Blood transfusion strategy, Meta-analysis

DOI: https://doi.org/10.21203/rs.3.rs-476215/v1

License: © This work is licensed under a Creative Commons Attribution 4.0 International License. Read Full License
Abstract

Background

Anemia is frequent in patients with acute myocardial infarction (AMI), and the optimal red blood cell transfusion strategy for patients with AMI and anemia is still controversial. We aimed to compare the efficacy of restrictive and liberal red cell transfusion strategies in patients with AMI and anemia.

Methods

We systematically searched PubMed, EMBASE, Web of Science, Cochrane Library, and Clinicaltrials.gov, from their inception until March 2021. Inclusion criteria were clinical trials that compared the efficacy of restrictive and liberal transfusion strategies in patients with AMI and anemia on all-cause mortality and major adverse cardiovascular events. The primary outcome was all-cause mortality, including overall mortality, in-hospital, or follow-up mortality. Risk ratios (RR) with 95% confidence intervals (CI) were presented and pooled by random-effects models.

Results

The search yielded a total of 6630 participants in six studies. Among the included patients, the average age ranged from 69.0 to 79.5 years and 2950 (44.5%) were men. A total of 2008 patients received restrictive red blood transfusion while 4622 patients were given liberal red blood transfusion. No difference was found in overall mortality and follow-up mortality between restrictive and liberal blood transfusion groups (RR=1.07, 95% CI=0.82–1.40, P=0.62; RR=0.89, 95% CI=0.56–1.42, P=0.62). However, restrictive transfusion was associated with a higher risk of in-hospital mortality compared with liberal transfusion (RR=1.22, 95% CI=1.00–1.50, P=0.05). No secondary outcomes, including follow-up reinfarction, stroke, and acute heart failure, differed significantly between the two groups. In addition, subgroup analysis showed no differences in overall mortality between the two groups based on sample size and design.

Conclusion

Restrictive and liberal red blood transfusion have a similar effect on overall mortality and follow-up mortality in patients with AMI and anemia. However, restrictive transfusion was associated with a higher risk of in-hospital mortality compared with liberal transfusion. The findings suggest that transfusion strategy should be evaluated in the more future researches.

Key Messages

- Restrictive and liberal red blood transfusion have a similar effect on overall mortality and follow-up mortality in patients with acute myocardial infarction and anemia.
- Restrictive transfusion was associated with a higher risk of in-hospital mortality compared with liberal transfusion. The findings suggest that transfusion strategy should be evaluated in the more future researches.

Introduction

Anemia is frequent in patients with acute myocardial infarction (AMI), with the reported rates of 15–43%[1], because of invasive procedures and antithrombotic therapy[2]. Anemia increases the incidence of adverse cardiovascular events, including short- and long-term mortality among patients with AMI[1, 3]. Red blood cell (RBC) transfusion increases oxygen delivery, rapidly improves symptoms in patients with acute myocardial ischemia, and is commonly used in clinical practice[4]. However, inappropriate blood transfusion may lead to circulatory overload and increased thrombogenicity, which can worsen the clinical outcomes[5–7]. Therefore, it is essential to select the optimal transfusion strategy in patients with AMI and anemia.

To date, the risks and benefits of optimal transfusion strategy, liberal or restricted transfusion, remain unclear in such patients. Although several well-conducted meta-analyses about the transfusion strategies have been published, they did not examine the subgroup of patients with AMI and anemia[8–10]. Observational studies have yielded conflicting results[11–13] and only two previous small randomized clinical trials (RCTs) (including 45 and 110 patients) have compared transfusion strategies in patients with AMI[14–15]. Recently, the first multicenter RCT with a relatively large sample size has compared liberal and restrictive RBC transfusion strategies in such settings[16], and the results showed that the restrictive transfusion resulted in a noninferior rate of adverse outcomes after 30 days.

However, no meta-analysis has specifically compared the outcomes of different transfusion strategies in patients with AMI and anemia. Therefore, we performed the present meta-analysis to assess the efficacy of restrictive transfusion versus liberal transfusion in such patients.

Methods

This meta-analysis was performed in accordance with the PRISMA guidelines[17]. The protocol was registered with PROSPERO in September 2020, number CRD420202 04670. Ethical approval and patient consent were not required because this study was based on previous studies.

2.1. Literature search strategy

We systematically searched five electronic databases, including PubMed, EMBASE, Web of Science, Cochrane Library, and Clinicaltrials.gov, from their inception until March 2021 for the comparative studies of restrictive transfusion and liberal transfusion in patients with AMI and anemia. Restrictive transfusion was defined as hemoglobin threshold ≤ 8 g/dL or hematocrit ≤ 24%, while liberal transfusion was defined as hemoglobin threshold ≤ 10 g/dL or hematocrit ≤ 30%[18]. In order to systematically search these electronic databases, search terms were constructed as follows: (Transfusion OR Blood
transfusion OR Red blood cell transfusion) AND (Myocardial infarction OR Acute myocardial infarction OR ST-segment evaluated myocardial infarction OR Non-ST-segment evaluated myocardial infarction OR Acute coronary syndrome OR Percutaneous coronary intervention). The search was not restricted for trials by type, language, or publication status. To screen for additional studies, the reference lists of the included articles and previous relevant meta-analyses were also carefully scanned. Additionally, the major international cardiology meetings (the European Society of Cardiology, the American Heart Association, and the American College of Cardiology) were also searched for relevant conference abstracts with complete results.

2.2. Study selection

The studies had to satisfy the following criteria to be included: (1) patients suffered from AMI and anemia; (2) one group received the liberal and the other group received the restrictive red blood cell transfusion strategy; and (3) data regarding the risk of in-hospital or follow-up mortality and in-hospital or follow-up major adverse cardiovascular events (MACEs) were available. MACEs were defined as reinfarction, stroke, or acute heart failure.

Studies designed to compare the efficacy between blood transfusion and non-transfusion patients with AMI but without separate data on different transfusion strategies were excluded. In addition, other exclusion criteria were as follows: (1) reports, meta-analyses, letters, and conference papers; (2) in vitro or preclinical animal studies; (3) enrolled pediatric patients; and (4) duplicate data. Two authors (YHL and YSZ) independently screened the articles based on titles and abstracts. We solved the disagreements and reached a consensus through discussion or arbitration by the third reviewer (YMH).

2.3. Outcomes

The primary end point was all-cause mortality, including overall mortality, inhospital mortality, or follow-up mortality (up to 6 months). The secondary outcomes were follow-up MACEs, including reinfarction, stroke, and acute heart failure.

2.4. Data extraction and quality assessment

Data extraction was independently carried out by two reviewers (YHL and YSZ) on the basis of prespecified extraction criteria. The following information was extracted from each included study: author, publication date, country, study design, sample size, patients’ characteristics, transfusion strategy, and outcomes. The third reviewer (YMH) checked for discrepancies and helped to settle the disagreements.

The quality of included studies was also independently evaluated by two reviewers (YHL and YSZ). The Cochrane Collaboration's risk of bias tool was used to assess the quality of RCTs[19], which comprised assessment of selection bias and other bias. To evaluate the quality of cohort studies, we used the Newcastle-Ottawa Scale[20], which consists of eight items about sampling methods, comparability, and accuracy of results. The disagreements were resolved through discussion among the reviewers and judged by the third reviewer (YMH).

2.5. Statistical analysis

The statistical analyses were carried out using Review Manager (version 5.3) and R software (version 4.0.2). Heterogeneity of studies was assessed using Q statistics and I². An I² value < 25% indicated low heterogeneity, 25%–50% denoted moderate heterogeneity, while the values over 50% defined severe heterogeneity. In order to minimize bias due to methodological differences between the studies, random-effects models were selected. Differences in results of all of the included studies were represented in the form of forest plots. Overall mortality was analyzed by subgroup analysis based on the study design and the number of cases. The sensitivity analysis of omission was carried out to evaluate the robustness of the results. Additionally, the funnel plot analysis and Egger's test were used to evaluate the publication bias. Risk ratios (RR) with 95% confidence intervals (CI) were presented and pooled by random-effects models. All the differences in the two-tailed test with P value less than 0.05 were considered to be statistically significant.

Results

3.1. Search results

Initially, 9108 articles were found through systematic search. After removing duplicates, 4977 articles were excluded based on title and abstract screening. Then, the full texts of 99 studies were reviewed to evaluate whether they met the inclusion criteria. Consequently, six studies meeting all of the criteria were finally included. The flow chart of the research selection process is shown in Figure 1.

3.2. Study characteristics and quality assessment

A total of six articles (6630 patients in total), published from 2001 to 2021, were included[4,13,14,15,16,21]. Three of the included studies were RCTs and three were cohort studies (one prospective study, two retrospective studies). Five articles included patients who received blood transfusions in the AMI setting, and only one article included patients with blood transfusions in the setting of acute coronary syndrome or stable angina (but data about AMI could be extracted). Among the included patients, the average age ranged from 69.0 to 79.5 years, and 2950 (44.5%) were men (Table 1). In addition, 2008 patients with AMI and anemia received restrictive red blood transfusion, while 4622 patients were given liberal red blood transfusion.

All of the included studies were of high quality, as confirmed by the Newcastle-Ottawa Scale and the Cochrane Collaboration’s risk of bias tool. The quality assessment of the eligible studies is shown in Table 2 and Figure S1.

3.3. Association of the transfusion strategy and outcome

There was no statistically significant difference in overall mortality between the restrictive transfusion group and the liberal transfusion group (RR, 1.07 [95% CI=0.82–1.40]; P=0.62; I²=66%), with the severe heterogeneity observed (Figure 2). Three studies and four studies evaluated the relationship between blood
transfusion strategies and in-hospital mortality or follow-up mortality, respectively. There was also no significant difference in follow-up mortality between the two groups (RR, 0.89 [95% CI=0.56–1.42]; P=0.62; I²=50%), while restrictive transfusion was associated with a relatively higher risk of in-hospital mortality compared with liberal transfusion (RR, 1.22 [95% CI=1.00–1.50]; P=0.05; I²=41%) (Figure S2).

In addition, no obvious difference was found in the secondary outcomes of reinfarction (RR, 0.82 [95% CI=0.38–1.74]; P=0.60; I²=0%), stroke (RR, 0.69 [95% CI=0.13–3.65]; P=0.66; I²=0%), and acute heart failure (RR, 0.74 [95% CI=0.16–3.46]; P=0.70; I²=74%) between the restrictive transfusion group and the liberal transfusion group (Figure 3).

3.4. Subgroup analysis

A predefined subgroup analysis of overall mortality according to study design and sample size was performed. The results remained similar to the primary analysis (Figure 4A and 4B).

3.5. Publication bias and sensitivity analysis

The asymmetric distribution of funnel plot suggested that there could be publication bias among the included studies (Figure S3). However, no publication bias was detected through Egger's test, with P value being 0.7829 for overall mortality. The sensitivity analysis of omission showed that removing a single study each time had no significant effect on the results (Figure S4).

Discussion

The present study showed no differences in overall mortality and follow-up mortality between the restrictive and liberal transfusion in patients with AMI and anemia. Moreover, no secondary outcomes differed significantly between the two groups. However, restrictive transfusion was associated with a higher risk of in-hospital mortality compared with liberal transfusion.

In patients with AMI, several studies have shown that blood transfusion was related to the increased risk of repeated myocardial infarction and short- and long-term mortality, especially for patients suffering from acute myocardial infarction[22–24]. A meta-analysis including 10 studies concluded that blood transfusion increased incidence of all-cause death in patients suffering from MI compared with the absence of blood transfusion[12]. Conversely, the findings of a multicenter study have shown that blood transfusion was associated with lower risk of in-hospital mortality in propensity-matched patients with AMI and indicated that previous observational reports of increased mortality with transfusion may have been influenced by selection bias[25]. The 2020 ESC Guideline for the management of patients with Non-ST-Elevation acute coronary syndromes recommended that these patients with anemia should not routinely receive RBC transfusion when hematocrit is above 25% or hemoglobin levels above 8 g/dl (class IIIb, level of evidence C)[26]. Given the results above, we should be cautious about the blood transfusion in patients with AMI and anemia in clinical practice.

RBC transfusion can rapidly increase oxygen delivery and improve some symptoms of the patients with AMI and anemia[4]. However, the threshold for blood transfusion is still controversial in this population. Previous meta-analysis which only included few patients with AMI (n = 154) found that there were no differences in mortality between restrictive and liberal transfusion strategies in subgroup of patients with AMI, but restrictive transfusion strategy was not recommended because of insufficient evidence[9]. Another meta-analysis of 11 RCTs also showed that it may not be safe to use a restrictive transfusion threshold of less than 80 g/L in patients with ongoing acute coronary syndrome or chronic cardiovascular disease because restrictive blood transfusion can increase the risk of acute coronary syndrome; however, there was no difference in 30-day mortality between the two transfusion strategies[8].

There had some deficiencies for previous meta-analysis and researches. Firstly, a limited number of studies with small sample sizes, comparing restrictive transfusion with liberal transfusion in patients with AMI were included, which tended to overestimate intervention effect estimates and could not make any relevant conclusions regarding intervention effects. Secondly, some of the abovementioned studies were not focus on the patients with AMI, which were different from other patient populations because of acute myocardial ischemia. These analyses included not only patients with myocardial infarction but also patients with other types of coronary artery disease. Until now, there has been insufficient evidence to prove which transfusion strategy is the optimal in patients with AMI. Therefore, we conducted a meta-analysis based on the new researches focus on the patients with AMI to compare the efficacy of restrictive and liberal transfusion strategies.

To date, three RCTs have evaluated the restrictive and liberal transfusion strategies in patients with AMI and anemia. Of those, two randomized pilot trials were performed to compare the efficacy between restrictive and liberal transfusion, but their findings were inconsistent. In one pilot trial, the results showed that the liberal transfusion strategy may be associated with worse clinical outcomes[15]. In contrast, another pilot trial demonstrated that the liberal transfusion strategy, compared with a more restrictive strategy, was able to reduce the incidence of major cardiac events and deaths among anemic patients with acute coronary syndrome or stable angina[14]. Recently, the first multicenter RCT compared liberal versus restrictive RBC transfusion strategies in patients with AMI and anemia[16], showing that the restrictive transfusion strategy not only was no less clinically effective than the liberal transfusion strategy, but it also saved blood. This RCT provided a more sufficient basis for clinical practice.

Based on the new researches in our meta-analysis, a half of the included studies were RCTs, which reduced the impact from confounding and other inherent bias that could affect the outcomes. Moreover, we only included studies with AMI patients, which led to robust pooled results to estimate the benefit of restrictive or liberal RBC transfusion in AMI patients. Our meta-analysis found that restrictive RBC transfusion for AMI patients did not affect overall mortality and the incidence of MACEs, compared with liberal RBC transfusion, although liberal RBC transfusion slightly reduced in-hospital mortality. The possible reason for this observation is that cardiac ischemia can occur at higher hemoglobin levels in patients with coronary heart disease[27], and liberal blood transfusion can alleviate myocardial ischemia, thereby reducing the risk of death. In addition, most of the patients included in present meta-analysis were
elderly patients with limited compensatory capacity of the heart and lungs when they suffered from myocardial infarction, so restrictive blood transfusion may increase in-hospital mortality.

Although liberal RBC transfusion may slightly reduce in-hospital mortality, there are many potential risks associated with more liberal transfusion strategy. First, liberal transfusion may increase the risk of hospital-acquired infections, compared with restrictive transfusion[28]. Second, liberal transfusion is associated with circulatory overload, which could increase the burden on the heart and energy expenditure. Third, the increase of RBC transfusion leads to an increase in platelet reactivity, which may be related to increased incidence of myocardial reinfarction and other advert myocardial events[25, 29]. Therefore, transfusion strategy for AMI and anemic patients should be evaluated in the more future researches.

Limitations

The present meta-analysis still has several limitations. Firstly, although a half of the included studies were RCTs, we also included three observational studies. The inherent bias of those studies could have affected the pooled outcomes. Secondly, some data about the outcomes (such as MACEs) were not completely available. So future studies should focus more on the comparison of follow-up MACEs between restrictive and liberal transfusion in patients with AMI and anemia. Thirdly, due to the lack of data on transfusion adverse reactions in the included studies, we were unable to evaluate the effects of different transfusion strategies on transfusion adverse reactions in patients with AMI and anemia. Fourthly, statistical heterogeneity was detected. Sample size, baseline characteristics of patients, study design and other reasons may have caused the heterogeneity. Finally, most of the patients included were American and older. Therefore, caution should be exercised when extending the conclusion of this study to a wider population. Although there were some limitations in this meta-analysis, the findings of this study could help to better understand the effects of different RBC transfusion strategies on patients suffering from AMI and anemia. More RCTs should be conducted in the future to verify the results of this meta-analysis.

Conclusion

Restrictive and liberal red blood transfusion have a similar effect on overall mortality and follow-up mortality in patients with AMI and anemia. However, restrictive transfusion was associated with a higher risk of in-hospital mortality compared with liberal transfusion. The findings suggest that transfusion strategy should be evaluated in the more future researches.

Abbreviations

AMI: Acute myocardial infarction; RBC: Red blood cell; RCTs: Randomized clinical trials; MACEs: Major adverse cardiovascular events; RR: Risk ratios; CI: Confidence intervals

Declarations

Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Availability of data and materials
All data generated or analyzed during this study are included in this published article.

Competing interests
The authors declare that they have no competing interests.

Funding
This work was supported by the Shuangqing Talent Program Project of Guangdong Provincial people's Hospital [Grant No. KJ012019095 to Y.H.L. and Grant No. KJ012019084 to P.C.H], and China Youth Research Funding (2017-CCA-VG-02), and Guangdong Provincial People's Hospital Clinical Research Fund (Y012018085), and the Key Project of Natural Science Foundation of Guangdong Province (2017B030311010).

Authors’ contributions
YHL and YSZ contributed equally to this work. NT and YHL conceived the study and designed the protocol. YSZ performed the literature search. YHL and YSZ selected the studies and extracted the relevant information. YSZ and YMH synthesised the data. YHL, YSZ and YMH wrote the first draft of the paper. All authors critically revised successive drafts of the paper and approved the final version.

Acknowledgements
Not applicable.
References

1. Sabatine MS, Morrow DA, Giugliano RP, Burton PB, Murphy SA, McCabe CH, Gibson CM, Braunwald E. Association of hemoglobin levels with clinical outcomes in acute coronary syndromes. Circulation. 2005;111(16):2042–49.

2. Salisbury AC, Amin AP, Reid KJ, Wang TY, Masoudi FA, Chan PS, Alexander KP, Bach RG, Spertus JA, Kosiborod M. Hospital-acquired anemia and inhospital mortality in patients with acute myocardial infarction. Am Heart J. 2011;162(2):300–9.e3.

3. Younge JO, Nauta ST, Akkerhuis KM, Deckers JW, van Domburg RT. Effect of anemia on short- and long-term outcome in patients hospitalized for acute coronary syndromes. Am J Cardiol. 2012;109(4):506–10.

4. Alexander KP, Chen AY, Wang TY, Rao SV, Newby LK, LaPointe NM, Ohman EM, Roe MT, Boden WE, Harrington RA, et al. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008;155(6):1047–53.

5. Merlín PA, Bauer KA, Oltrona L, Ardissino D, Cattaneo M, Belli C, Mannucci PM, Rosenberg RD. Persistent activation of coagulation mechanism in unstable angina and myocardial infarction. Circulation. 1994;90(1):61–8.

6. Sacco RL, Sacco RL, Sacco RL, Sacco RL, Sacco RL, Sacco RL, Sacco RL, Sacco RL, Sacco RL, Sacco RL. Transfusing red blood cells stored in citrate phosphate dextrose adenine-1 for 28 days fails to improve tissue oxygenation in rats. Crit Care Med. 1997;25(5):726–32.

7. Figuera J, Monasterio Y, Lidón RM, Nieto E, Soler-Soler J. Thrombin formation and fibrinolytic activity in patients with acute myocardial infarction or unstable angina: in-hospital course and relationship with recurrent angina at rest. J Am Coll Cardiol. 2000;36(7):2036–43.

8. Docherty AB, O’Donnell R, Brunskill S, Trivella M, Doree C, Holst L, Parker M, Gregersen M, Pinheiro de Almeida J, Walsh TS, et al. Effect of restrictive versus liberal transfusion strategies on outcomes in patients with cardiovascular disease in a non-cardiac surgery setting: systematic review and meta-analysis. BMJ. 2016;352:i3351.

9. Ripollès Melchor J, Casans Francés R, Espinosa Á, Martínez Hurtado E, Navarro Pérez R, Abad Gurumeta A, Basora M, Calvo Vecino JM, EAR Group. Anesthesia Evidence Review. Restrictive versus liberal transfusion strategy for red blood cell transfusion in critically ill patients and in patients with acute coronary syndrome: a systematic review, meta-analysis and trial sequential analysis. Minerva Anestesiol. 2016;82(5):582–8.

10. Wang Y, Shi X, Wen M, Chen Y, Zhang Q. Restrictive versus liberal blood transfusion in patients with coronary artery disease: a meta-analysis. Curr Med Res Opin. 2017;33(4):761–8.

11. Carson JL, Carless PA, Hébert PC. Outcomes using lower vs higher hemoglobin thresholds for red blood cell transfusion. JAMA. 2013;309(1):83–4.

12. Chatterjee S, Wetterleslev J, Sharma A, Lichstein E, Mukherjee D. Association of blood transfusion with increased mortality in myocardial infarction: a meta-analysis and divergence-adjusted study sequential analysis. JAMA Intern Med. 2013;173(2):132–9.

13. Wu WC, Rathore SS, Wang Y, Radford MJ, Krumholz HM. Blood transfusion in elderly patients with acute myocardial infarction. N Engl J Med. 2001;345(17):1230–36.

14. Carson JL, Brooks MM, Abbott JD, Chaitman B, Kelsey SF, Triulzi DJ, Srinivas V, Menegus MA, Marroquin OC, Rao SV, et al. Liberal versus restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J. 2013;165(6):964–71.e1.

15. Cooper HA, Rao SV, Greenberg MD, Rumsey MP, McKenzie M, Alcorn KW, Panza JA. Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study). Am J Cardiol. 2011;108(8):1108–11.

16. Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, Cachanado M, Durand-Zaleski I, Arnaiz JA, Martinez-Sellés M, Silvain J, Ariza-Solé A, et al. Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial. JAMA. 2021;325(6):552–60.

17. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Joannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

18. Higgins JP, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

19. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaufre L, Hildebrand K, et al. Liberal or restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J. 2013;165(6):964–71.e1.

20. Cooper HA, Rao SV, Greenberg MD, Rumsey MP, McKenzie M, Alcorn KW, Panza JA. Conservative versus liberal red cell transfusion in acute myocardial infarction (the CRIT Randomized Pilot Study). Am J Cardiol. 2011;108(8):1108–11.

21. Ducrocq G, Gonzalez-Juanatey JR, Puymirat E, Lemesle G, Cachanado M, Durand-Zaleski I, Arnaiz JA, Martinez-Sellés M, Silvain J, Ariza-Solé A, et al. Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial. JAMA. 2021;325(6):552–60.

22. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Joannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ. 2009;339:b2700.

23. Carson JL, Terrin ML, Noveck H, Sanders DW, Chaitman BR, Rhoads GG, Nemo G, Dragert K, Beaufre L, Hildebrand K, et al. Liberal or restrictive transfusion thresholds for patients with symptomatic coronary artery disease. Am Heart J. 2013;165(6):964–71.e1.

24. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Shekelle PG,-de Almeida J, Walsh TS, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;352:i1351.

25. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, Savovic J, Schulz KE, Weeks L, Sterne JA, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;352:i5928.

26. Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–5.

27. Aronson D, Dann EJ, Bonstein L, Blich M, Kapeliovich M, Beyar R, Markiewicz W, Hammerman H. Impact of red blood cell transfusion on clinical outcomes in patients with acute myocardial infarction. Am J Cardiol. 2008;102(2):115–9.

28. Putot A, Zeller M, Zeller M, Zeller M, Zeller M, Zeller M, Zeller M, Zeller M, Zeller M, Zeller M. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008;155(6):1047–53.

29. Gligorijević G, Gligorijević G, Gligorijević G, Gligorijević G, Gligorijević G, Gligorijević G, Gligorijević G, Gligorijević G, Gligorijević G, Gligorijević G. Transfusion practice and outcomes in non-ST-segment elevation acute coronary syndromes. Am Heart J. 2008;155(6):1047–53.

30. Tajstra M, Gąsior M, Gierlotka M, Pres D, Hawranek M, Kuliczkowski W, Szkołdorowski J, Poloński L. Comparison between five-year mortality of patients with and without red blood cell transfusion after percutaneous coronary intervention for ST-elevation acute myocardial infarction. Kardiol Pol. 2013;71(10):1029–35.

31. Salisbury AC, Reid KJ, Marso SP, Amin AP, Alexander KP, Wang TY, Spertus JA, Kosiborod M. Blood transfusion during acute myocardial infarction: association with mortality and variability across hospitals. J Am Coll Cardiol. 2014;64(8):811–9.
26. Collet JP, Thiele H, Barbato E, Barthélémy O, Bauersachs J, Bhatt DL, Dendale P, Dorobantu M, Edvardsen T, Folliguet T, et al. 2020 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2020;ehaa575.

27. Levy PS, Kim SJ, Eckel PK, Chavez R, Ismail EF, Gould SA, Ramez Salem M, Crystal GJ. Limit to cardiac compensation during acute isovolemic hemodilution: influence of coronary stenosis. Am J Physiol. 1993;265(1 Pt 2):H340–9.

28. Rohde JM, Dimcheff DE, Blumberg N, Saint S, Langa KM, Hickner A, Rogers MA. Health care-associated infection after red blood cell transfusion: a systematic review and meta-analysis. JAMA. 2014;311(13):1317–26.

29. Silvain J, Abtan J, Kerneis M, Martin R, Finzi J, Vignalou JB, Barthélémy O, O'Connor SA, Luyt CE, Brechot N, et al. Impact of red blood cell transfusion on platelet aggregation and inflammatory response in anemic coronary and noncoronary patients: the TRANSFUSION-2 study (impact of transfusion of red blood cell on platelet activation and aggregation studied with flow cytometry use and light transmission aggregometry). J Am Coll Cardiol. 2014;63(13):1289–96.

### Tables

#### Table 1. Characteristics of included studies in this meta-analysis.

| Study       | Region | Study design | Transfused patients | Types of MI | Restrictive strategy (Transfusion threshold) | Liberal strategy (Transfusion threshold) | Average age (years) | Male No. (%) | Baseline Hb(g/dl)/Hct(%) |
|-------------|--------|--------------|---------------------|-------------|---------------------------------------------|------------------------------------------|---------------------|--------------|-------------------------|
| Wu, 2001    | USA    | Cohort       | 1356                | STEMI       | Hct ≤ 24%                                   | Hct ≤ 30%                                | 79.5                | 79.4         | 112 (41) | 398 (37) | 79.4 |
| Alexander, 2008 | USA | Cohort        | 4291               | Non-STEMI   | Hct ≤ 24%                                   | Hct ≤ 30%                                | 76.0                | 76.6         | 578 (45) | 1303 (44) | -/29.0 |
| Aronson, 2008 | USA | Cohort       | 192                | STEMI       | Hb ≤ 8 g/dl                                 | Hb > 8 g/dl                              | 69.0                | 69.0         | 21 (58)  | 89 (57)  | -/33.8 |
| Cooper, 2011 | USA    | RCT          | 45                 | STEMI       | Hct < 24%                                   | Hct < 30%                                | 70.3                | 76.4         | 13 (54)  | 10 (48)  | -/27.5 |
| Carson, 2013 | USA    | RCT          | 80                 | STEMI       | Hb ≥ 8 g/dl                                 | Hb < 10 g/dl                             | 74.3                | 67.3         | 19 (49)  | 21 (51)  | 8.97/9 |
| Ducrocq 2021 | FranceSpain | RCT      | 666                | STEMI       | Hb ≤ 8 g/dl                                 | Hb ≤ 10 g/dl                             | 78.0                | 76.0         | 201 (59) | 184 (57) | 9.0/9  |

MI=Myocardial infarction; STEMI=ST-segment elevation myocardial infarction; Non-STEMI=Non-ST-segment elevation myocardial infarction; Hct=Hematocrit; Hb=Hemoglobin; RT=Restrictive transfusion; LT=Liberal transfusion; HF=Heart failure.

#### Table 2. Results of quality assessment using the Newcastle-Ottawa Scale for included studies (Cohort Studies)

| Study       | Adequate definition of cases | Representativeness of the cases | Selection of controls | Definition of controls | Control for important factora | Ascertainment of exposure | Same method of ascertainment for cases and controls | Non-response rate | Scores |
|-------------|-----------------------------|---------------------------------|-----------------------|------------------------|-------------------------------|---------------------------|---------------------------------------------------|------------------|--------|
| Wu (2001)   |                             |                                |                       |                        |                               |                           |                                                   |                  | 9      |
| Alexander (2008) |                             |                                |                       |                        |                               |                           |                                                   |                  | 9      |
| Aronson (2008) |                             |                                |                       |                        |                               |                           |                                                   |                  | 9      |

a, a maximum of 2 stars can be allotted in this category, one for age, the other for other controlled factors.

### Figures
The flow diagram indicated the process of study selection.

| Study or Subgroup        | Restrictive Events | Liberal Events | M-H Risk Ratio | Year |
|--------------------------|--------------------|----------------|----------------|------|
| Wu 2001                  | 195                | 271            | 1.08 [1.00, 1.18] | 2001 |
| Alexander 2008           | 153                | 1293           | 1.38 [1.14, 1.67] | 2008 |
| Aronson 2008             | 5                  | 36             | 0.44 [0.19, 1.03] | 2008 |
| Cooper 2011              | 4                  | 24             | 1.75 [0.36, 8.61] | 2011 |
| Carson 2013              | 5                  | 42             | 4.52 [0.55, 37.01] | 2013 |
| Ducrocq 2021             | 19                 | 342            | 0.72 [0.40, 1.28] | 2021 |

Total (95% CI) 2008 4622 100.0% 1.07 [0.82, 1.40]

Total events 381 1054

Heterogeneity: $\tau^2 = 0.05$; $Chi^2 = 14.57$, df = 5 ($P = 0.01$); $I^2 = 66$

Test for overall effect: $Z = 0.50$ ($P = 0.62$)

Forest plot for the association between blood transfusion strategies with overall mortality.
Figure 3

Forest plot for the association between blood transfusion strategies with secondary outcomes
Figure 4

Subgroup analysis of overall mortality for blood transfusion strategies according to study design and sample size: A: Study design; B: study sample size.

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- supplementarymaterials20210428.docx